Sudeep Pharma Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2nhwlr5oz2e32nnakf8rrr0u.pdf

Key Takeaways


The Battery Materials Bet Is De-Risking Rapidly

Shanil Bhayani: "I think how we are positioning Sudeep is an alternative to China to support customers kind of fulfill the regulatory requirements in critical markets."

Core Nutrition Business: Volume-Led, Geography-Widening


Specialty Ingredients: The Growth Engine Firing


Liposomal Platform: The Next Pipeline

Shanil Bhayani: "We will start to see a revenue contribution from this maybe in H2 FY '27 and more significantly in FY28, as we have just completed our clinical studies on these two products."

Margins, Tariffs & the US Opportunity

Shanil Bhayani: "We have not taken a margin hit or margin dilution by accepting the tariff impact. Majority, I would say, maybe at least across 90% of the business where tariff was effective, we have passed on the tariff impact to the customer."

Capacity Build-Out: Phased and Demand-Linked


Guidance & Commitments

CommitmentSpecificsTimeline
Nandesari greenfield commissioningFacility on track for commissioningQ4 FY26 (March 2026)
Nandesari utilization rampScale to 30-40% utilization, then ramp furtherFY28 onwards
Dahej Phase 1 commissioning25,000 MTPA battery-grade iron phosphate capacityEarly 2027
Battery materials revenue contributionFirst revenue from battery materialsFY28
Battery materials asset turnsApproximately 3x, similar to core businessAt commercialization
Liposomal revenue contributionInitial revenue expectedH2 FY27, more significantly in FY28
Specialty ingredients growth rate30-35% growth momentum to continueNext two years
NSS growth rate~15% organic growth plus Sudeep-led project upsideNext one to two years
Overall margin profileMaintain historically maintained levels, no significant changeFY27
US tariff impact on marginsNo margin dilution; 90%+ passed through to customersCurrent, ongoing
Battery materials depreciationDepreciation begins only when revenue startsFY28

Key Metrics

MetricQ3 FY26
Total income₹179.2 cr, +52% YoY vs ₹118 cr in Q3 FY25
EBITDA₹66.8 cr, +60% YoY vs ₹41.7 cr in Q3 FY25
EBITDA margin37.3%
PAT₹47.7 cr, +66% YoY vs ₹28.7 cr in Q3 FY25
Total income (9M FY26)₹482.1 cr, +38% YoY vs ₹350 cr in 9M FY25
EBITDA margin (9M FY26)37.6% vs 39.1% in 9M FY25
Revenue excluding NSS₹156 cr for Q3, +35.26% YoY (per an analyst's math)
Revenue excluding NSS (9M FY26)₹416 cr, +21% YoY (per an analyst's math)
Export contribution62% of total income; domestic contributed 38%
Specialty business contribution41% of total income; pharma, food and nutrition contributed 59%
India domestic market growthnearly 20% in Q3
Networking capital days~180 days
Nandesari Greenfield facility capacity51,200 metric tons, commissioning March 2026
Battery-grade iron phosphate capacity addition5,000 tons at existing facilities
Battery materials Phase 1 capexapproximately ₹300 cr, includes land for entire 100,000 ton facility
Total capex for 100,000 ton battery facilityapproximately ₹550 cr to ₹600 cr
Specialty ingredients capacity utilizationclose to 40%
Pharma food nutrition capacity utilizationaround 65% to 70%
NSS contribution₹17-odd cr of revenue
Battery materials customer engagements34 customers across the battery value chain
Battery materials customer approvals~70% of 34 customers have approved and validated samples
US business tariff exposure50% of US business was subject to tariff; tariff impact passed on to customer across at least 90% of that business